Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry.

By G. Fonarow, W. G. Stough, W. Abraham, N. Albert, M. Gheorghiade, B. Greenberg, C. O'connor, Jie-Lena Sun, C. Yancy, James B. Young. Journal of the American College of Cardiology, 2007

1,159 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/00b2190f2ed11de193fcf9bf60b7e8affa10f876

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. C. Yancy
2. B. Bozkurt
3. M. Jessup
4. C. Lam
5. G. Fonarow
6. J. Butler
7. E. Donal
8. M. Drazner

Citations in the corpus

• 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. (2013, background): “EF is considered important in classification of patients with HF because of differing patient demographics, comorbid conditions, prognosis, and response to therapies (36) and because most clinical trials selected patients based on EF.”
• Impact of Non-Cardiac Comorbidities on Morbidity and Mortality in a Predominantly Male Population with Heart Failure and Preserved versus Reduced Ejection Fraction (2012, background): “In addition, studies have also shown that although the clinical signs and symptoms of HF are similar between HFpEF and HFrEF, patients with HFpEF are less likely to receive diuretic agents for congestion, anticoagulation therapy for atrial fibrillation, smoking cessation counseling, complete dischar”
• Epidemiology and clinical course of heart failure with preserved ejection fraction (2011, background): “5%.(24,25) The long-term mortality rates seem more variable in the reported”
• Cardiac T1 Mapping and Extracellular Volume (ECV) in clinical practice: a comprehensive review (2016, background): “Both heart failure patients with reduced and preserved ejection fraction experienced similar rates of mortality and morbidity [52].”
• Cardiorenal syndrome. (2008, unknown): “Among these patients, pre-morbid chronic renal dysfunction is a common occurrence and predisposes them to AKI (12,13).”
• Heart failure with preserved ejection fraction. (2006, background): “However, data from the general population of unselected patients reported that mortality of HFPEF may be comparable to that of SHF((8,9)) How can we accept this controversy in mortality? The clue is the criteria of HFPEF diagnosis, is it LVEF>50%, >45%, or 40%? This could reflect the variability in ”
• 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “EF is considered important in classification of patients with HF because of differing patient demographics, comorbid conditions, prognosis, and response to therapies (35) and because most clinical trials selected patients based on EF.”